WO2007146712A3 - Therapy using cytokine inhibitors - Google Patents

Therapy using cytokine inhibitors Download PDF

Info

Publication number
WO2007146712A3
WO2007146712A3 PCT/US2007/070547 US2007070547W WO2007146712A3 WO 2007146712 A3 WO2007146712 A3 WO 2007146712A3 US 2007070547 W US2007070547 W US 2007070547W WO 2007146712 A3 WO2007146712 A3 WO 2007146712A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
therapy
cytokine
cytokine inhibitors
compounds
Prior art date
Application number
PCT/US2007/070547
Other languages
French (fr)
Other versions
WO2007146712A2 (en
Inventor
Constance A Crowley
Nancy G J Delaet
Justin Ernst
Carrie Gail Grove
Bonnie Hepburn
Bernard King
Christopher J Larson
Stephen Miller
Kent Pryor
Lewis J Shuster
Original Assignee
Kemia Inc
Constance A Crowley
Nancy G J Delaet
Justin Ernst
Carrie Gail Grove
Bonnie Hepburn
Bernard King
Christopher J Larson
Stephen Miller
Kent Pryor
Lewis J Shuster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc, Constance A Crowley, Nancy G J Delaet, Justin Ernst, Carrie Gail Grove, Bonnie Hepburn, Bernard King, Christopher J Larson, Stephen Miller, Kent Pryor, Lewis J Shuster filed Critical Kemia Inc
Priority to AU2007257959A priority Critical patent/AU2007257959A1/en
Priority to CA2691214A priority patent/CA2691214A1/en
Priority to EP07798190A priority patent/EP2035005A4/en
Publication of WO2007146712A2 publication Critical patent/WO2007146712A2/en
Publication of WO2007146712A3 publication Critical patent/WO2007146712A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods of treating, preventing, modifying and managing cytokine-mediated disorders or related disorders, which comprise the administration of a compound, such as a cytokine inhibitor, alone or in combination with known therapeutics. The invention also relates to pharmaceutical compositions and dosing regimens using the disclosed compounds. In particular, the invention relates to the use of compounds as disclosed herein, optionally in conjunction with other therapies, for the treatment of autoimmune diseases, inflammatory diseases, cardiovascular diseases, and cancer.
PCT/US2007/070547 2006-06-09 2007-06-06 Therapy using cytokine inhibitors WO2007146712A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2007257959A AU2007257959A1 (en) 2006-06-09 2007-06-06 Therapy using cytokine inhibitors
CA2691214A CA2691214A1 (en) 2006-06-09 2007-06-06 Therapy using cytokine inhibitors
EP07798190A EP2035005A4 (en) 2006-06-09 2007-06-06 Therapy using cytokine inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US81226806P 2006-06-09 2006-06-09
US60/812,268 2006-06-09
US83307806P 2006-07-24 2006-07-24
US60/833,078 2006-07-24
US83527006P 2006-08-03 2006-08-03
US60/835,270 2006-08-03

Publications (2)

Publication Number Publication Date
WO2007146712A2 WO2007146712A2 (en) 2007-12-21
WO2007146712A3 true WO2007146712A3 (en) 2008-11-27

Family

ID=38832677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/070547 WO2007146712A2 (en) 2006-06-09 2007-06-06 Therapy using cytokine inhibitors

Country Status (8)

Country Link
EP (1) EP2035005A4 (en)
AR (1) AR061273A1 (en)
AU (1) AU2007257959A1 (en)
CA (1) CA2691214A1 (en)
CL (1) CL2007001670A1 (en)
PE (1) PE20080935A1 (en)
TW (1) TW200814998A (en)
WO (1) WO2007146712A2 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1986633T3 (en) 2006-02-10 2015-01-30 Summit Oxford Ltd Treatment of duchenne muscular dystrophy
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063142A1 (en) 2006-10-04 2008-12-30 Pharmacopeia Inc DERIVATIVES OF 2- (BENCIMIDAZOLIL) PURINE AND PURINONES 6-USEFUL SUBSTITUTES AS IMMUNOSUPPRESSORS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
JP5453258B2 (en) * 2007-07-13 2014-03-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Heterocyclic modulators of cannabinoid receptors
EP2170396B1 (en) 2007-08-03 2016-12-21 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
EP2352730A4 (en) * 2008-11-07 2012-04-25 Lundbeck & Co As H Biologically active amides
EP2438059A1 (en) 2009-06-05 2012-04-11 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
US20110117055A1 (en) * 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
WO2011076749A2 (en) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR102113960B1 (en) 2010-03-30 2020-05-21 베르선 코포레이션 Multisubstituted aromatic compounds as inhibitors of thrombin
US9035072B2 (en) 2010-04-22 2015-05-19 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
BR112014005617A2 (en) 2011-10-21 2017-06-13 Abbvie Inc combination treatment (for example with abt-072 or abt -333) of daas for use in the treatment of hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2572329B1 (en) 2011-10-21 2017-08-24 Abbvie Inc. COMBINATION OF AT LEAST TWO DIRECT ACTION AND RIBAVIRIN AGENTS, BUT NOT INTERFERONED, FOR USE IN THE HCV TREATMENT
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
EP2968297B1 (en) 2013-03-15 2018-09-26 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones
PL3424534T3 (en) 2014-04-15 2021-11-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2016044662A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CA2968884A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
WO2016138532A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CA3021424C (en) * 2015-06-12 2023-03-21 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
TW201718581A (en) 2015-10-19 2017-06-01 英塞特公司 Heterocyclic compounds as immunomodulators
ES2928856T3 (en) 2015-11-19 2022-11-23 Incyte Corp Heterocyclic compounds as immunomodulators
CR20180328A (en) 2015-12-15 2018-08-09 Astrazeneca Ab ISOINDOL COMPOUNDS
UA126113C2 (en) 2015-12-22 2022-08-17 Інсайт Корпорейшн Heterocyclic compounds as immunomodulators
CA3012846A1 (en) 2016-02-16 2017-08-24 Massachusetts Institute Of Technology Max binders as myc modulators and uses thereof
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3468604T3 (en) * 2016-06-08 2021-07-12 Support-Venture Gmbh Pharmaceutical combinations for treating cancer
WO2017222976A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (en) 2016-08-29 2021-04-28 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
MY183036A (en) 2016-12-20 2021-02-08 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
ES2874756T3 (en) 2016-12-22 2021-11-05 Incyte Corp Triazolo [1,5-A] pyridine derivatives as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112019012957A2 (en) 2016-12-22 2019-11-26 Incyte Corp tetrahydroimidazo [4,5-c] pyridine derivatives as inducers of internalization of pd-11
KR20200018440A (en) * 2017-05-15 2020-02-19 리커리엄 아이피 홀딩스, 엘엘씨 Painkiller compounds
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN111646986B (en) * 2017-09-13 2022-03-25 厦门稀土材料研究所 Nicotinic acid derivative and preparation method and application thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
MX2020006587A (en) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors.
SI3774791T1 (en) 2018-03-30 2023-04-28 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3790877T3 (en) 2018-05-11 2023-04-24 Incyte Corp TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNE MODULATORS
CA3121199A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN111825605B (en) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 Aryl ketone amide compound and preparation method and application thereof
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
BR112022005826A2 (en) 2019-09-30 2022-06-21 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CN114845709A (en) * 2019-11-05 2022-08-02 德米拉公司 MRGPRX2 antagonists for use in treating inflammatory disorders
MX2022005651A (en) 2019-11-11 2022-07-27 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor.
CR20220316A (en) 2019-12-06 2022-10-07 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
JP2023548859A (en) 2020-11-06 2023-11-21 インサイト・コーポレイション Process for making PD-1/PD-L1 inhibitors and their salts and crystalline forms
CN113209112B (en) * 2021-02-06 2021-12-24 广州市朝利良生物科技有限公司 Novel coronavirus resistant medicine based on ACE2 and S protein binding target and application thereof
CN117794920A (en) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamides as sodium channel modulators
WO2024059220A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107399A1 (en) * 2003-09-11 2005-05-19 Kemia, Inc. Cytokine inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445003A1 (en) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107399A1 (en) * 2003-09-11 2005-05-19 Kemia, Inc. Cytokine inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2035005A4 *

Also Published As

Publication number Publication date
CA2691214A1 (en) 2007-12-21
AR061273A1 (en) 2008-08-13
PE20080935A1 (en) 2008-08-02
AU2007257959A1 (en) 2007-12-21
CL2007001670A1 (en) 2008-01-18
WO2007146712A2 (en) 2007-12-21
EP2035005A2 (en) 2009-03-18
TW200814998A (en) 2008-04-01
EP2035005A4 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
WO2007146712A3 (en) Therapy using cytokine inhibitors
WO2006091862A3 (en) Cytokine inhibitors and their use in therapy
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2008070041A3 (en) Inhibitors of akt activity
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2008115974A3 (en) Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2006135627A3 (en) Inhibitors of akt activity
WO2008024439A3 (en) 4-aminoquinazoline derivatives and methods of use thereof
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MX346186B (en) Protein kinase inhibitors.
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2007008502A3 (en) Inhibitors of checkpoint kinases
WO2010039742A3 (en) Methods to reduce b-helper t cells to treat autoimmune diseases
WO2009124103A3 (en) Combination therapies comprising par1 antagonists with par4 antagonists
WO2007081572A3 (en) Inhibitors of checkpoint kinases
WO2006074281A3 (en) Inhibitors of checkpoint kinases
WO2010065069A3 (en) Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07798190

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007257959

Country of ref document: AU

Ref document number: 2007798190

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007257959

Country of ref document: AU

Date of ref document: 20070606

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2691214

Country of ref document: CA